VisMederi Holding

Improving human health

Vismederi Holding

Vismederi Holding is the company that holds a qualified share of the companies that are part of the VisMederi Group. The Group of Vismederi Holding operates in various business areas all related to Research and Innovation in the fields of Public Health, Life Sciences and Biotechnologies and is composed of VisMederi Srl, VisMederi Research Srl, VisMederi Life Sciences Srl, VisMederi Textyle Srl, VisMederi Pharma Srl, ETHS – Education and Training for Health Sciences Srl with single shareholder, Accurange Srl.

Vismederi Holding
0Mln €

Revenues

0

Employees 

0Paesi

Global Partnerships

Vismederi Holding: latest news

All the news of the group

Jun 12 2024

Important international study in the field of Monkey Pox and Vaccinia Virus

Another important international study in the field of Monkey Pox and Vaccinia Virus: a sero-epidemiological study assessing the neutralizing...
Jun 04 2024

Students from Kent State University visit VisMederi

At the heart of research and innovation, the Vismederi Foundation warmly welcomed a group of American students from Kent State University at the...
May 22 2024

VIII International Conference and Exhibition IVW 2024 in Siena

The eighth edition of the "Influenza Vaccines for the World—IVW 2024" conference and exhibition is currently taking place in Siena (May 21–23,...
May 10 2024

VisMederi and the International Vaccine Institute have formed a new partnership to accelerate vaccine development in developing countries.

VisMederi and the International Vaccine Institute have formed a new partnership to accelerate vaccine development in developing countries....
Apr 29 2024

VisMederi Diagnostics opens a new collection point in Siena

Our new collection point will soon open at the Fisiomedical Center, located at Via Cesare Battisti 24, in Siena. We are already present at the...
Apr 16 2024

Simone Paletti, Chief Financial Officer, speaker at the key finance forum in Milan organized by “Comunicazione Italiana”

Simone Paletti, Chief Financial Officer at VisMederi Group, recently attended a key finance forum in Milan organized by "Comunicazione Italiana"....
Apr 16 2024

VisMederi Group at the World Vaccine Congress in Washington, D.C.

VisMederi Group attended the World Vaccine Congress in Washington, D.C., acknowledged as the most significant and longstanding event dedicated to...
Apr 16 2024

VisMederi has achieved a distinguished place in the prestigious FT 1000 ranking by the Financial Times

VisMederi has achieved a distinguished place in the prestigious FT 1000 ranking by the Financial Times, securing the 346th position among Europe's...
Apr 16 2024

VisMederi at the University of Siena’s prestigious event “USiena Game”

Elisa Mennitto, Chief Facilities and Lab Officer, represented VisMederi at the University of Siena's prestigious event "USiena Game". Addressing...
Jan 25 2024

Our manuscript “#CEPI Centralized Laboratory Network: a qualification analysis” has been published in The Lancet Microbe Online

Our manuscript "#CEPI Centralized Laboratory Network: a qualification analysis" has been published in The Lancet Microbe Online. This publication...

Where we

are

 

 

 

 

 

 

The

founder

Emanuele Montomoli is Full Professor of Hygiene and Public Health at the University of Siena, Italy. He received his BSc and MSc in Life Sciences from the University of Siena, Italy in 1997 and he earned his MBiochem in 2001.

Comments Box SVG iconsUsed for the like, share, comment, and reaction icons

Another important international study in the field of Monkey Pox and Vaccinia Virus: a sero-epidemiological study assessing the neutralizing response following smallpox vaccination.

The study was conducted in collaboration with VisMederi, the University of Siena, the University of Kent, and the Biomedical Primate Research Centre.

Read the research article here: www.vismederiholding.com/important-international-study-in-the-field-of-monkey-pox-and-vaccinia-vi...

#VisMederi #Monkeypox #VaccinaVirus #smallpox #seroepidemiologicalstudy
#UniversityOfKent #biomedicalprimateresearchCentre #researcharticles

********

Un altro importante studio internazionale nel campo del vaiolo delle scimmie e dei vaccini: uno studio siero-epidemiologico che valuta la risposta neutralizzante dopo la vaccinazione antivaiolosa”. Lo studio è stato condotto in collaborazione con VisMederi, l’Università di Siena, l’Università di Kent e il Biomedical Primate Research Centre.



Leggi qui lo studio: www.vismederiholding.com/it/important-international-study-in-the-field-of-monkey-pox-and-vaccinia...

#VisMederiGroup #vaiolodellescimmie
... See MoreSee Less

Another important international study in the field of Monkey Pox and Vaccinia Virus: a sero-epidemiological study assessing the neutralizing response following smallpox vaccination.

The study was conducted in collaboration with VisMederi, the University of Siena, the University of Kent, and the Biomedical Primate Research Centre.

Read the research article here: https://www.vismederiholding.com/important-international-study-in-the-field-of-monkey-pox-and-vaccinia-virus/

#VisMederi #Monkeypox #VaccinaVirus #smallpox #seroepidemiologicalstudy 
#UniversityOfKent #biomedicalprimateresearchCentre #researcharticles 

********

Un altro importante studio internazionale nel campo del vaiolo delle scimmie e dei vaccini: uno studio siero-epidemiologico che valuta la risposta neutralizzante dopo la vaccinazione antivaiolosa”. Lo studio è stato condotto in collaborazione con VisMederi, l’Università di Siena, l’Università di Kent e il Biomedical Primate Research Centre.

 

Leggi qui lo studio: https://www.vismederiholding.com/it/important-international-study-in-the-field-of-monkey-pox-and-vaccinia-virus/

#VisMederiGroup #vaiolodellescimmie

We were delighted to host students from Kent State University. An educational journey that bridges theory and practice, highlighting the significance of research and innovation.

Read the full article here: www.vismederiholding.com/students-from-kent-state-university-visit-vismederi/

#VisMederi #GlobalEducation #ScienceInAction #KentUniverisity

*********
Abbiamo avuto il piacere di ospitare studenti della Kent State University. Un’esperienza formativa che unisce teoria e pratica, sottolineando l’importanza della ricerca e dell’innovazione.

Leggi l'articolo: www.vismederiholding.com/it/students-from-kent-state-university-visit-vismederi/

#VisMederiGroup #EducazioneGlobale #ScienzaInAzione
... See MoreSee Less

We were delighted to host students from Kent State University. An educational journey that bridges theory and practice, highlighting the significance of research and innovation. 

Read the full article here: https://www.vismederiholding.com/students-from-kent-state-university-visit-vismederi/

#VisMederi #GlobalEducation #ScienceInAction #KentUniverisity

*********
Abbiamo avuto il piacere di ospitare studenti della Kent State University. Un’esperienza formativa che unisce teoria e pratica, sottolineando l’importanza della ricerca e dell’innovazione. 

Leggi larticolo: https://www.vismederiholding.com/it/students-from-kent-state-university-visit-vismederi/

#VisMederiGroup #EducazioneGlobale #ScienzaInAzioneImage attachmentImage attachment

We are pleased to announce the publication of an important paper on the full validation of the Lentiviral Pseudo-types Neutralization assay for Lassa Virus, one of the WHO Blue Print viruses.

This significant work was accomplished in collaboration with Prof. Nigel Temperton and the University of Kent.

This is a notable achievement and a proud moment to share with the scientific community.

Read the full article here: f1000research.com/articles/13-534

#LassaVirus #WHOBlueprint #ScientificResearch #Collaboration #UniversityOfKent #NigelTemperton #Virology #ResearchAchievement #vismederi
*****************
Siamo lieti di annunciare la pubblicazione di un importante articolo sulla validazione completa del saggio di neutralizzazione dei pseudo-tipi lentivirali per il virus Lassa, uno dei virus Blue Print dell'OMS. Questo significativo lavoro è stato realizzato in collaborazione con il Prof. Nigel Temperton e l'Università del Kent.

Questo è un notevole traguardo e un momento di orgoglio da condividere con la comunità scientifica.

Leggi l'articolo: f1000research.com/articles/13-534

#VisMederigroup #VirusLassa #OMSBlueprint #RicercaScientifica #Collaborazione #UniversitàDelKent #Virologia #TraguardoRicerca
... See MoreSee Less

We are pleased to announce the publication of an important paper on the full validation of the Lentiviral Pseudo-types Neutralization assay for Lassa Virus, one of the WHO Blue Print viruses. 

This significant work was accomplished in collaboration with Prof. Nigel Temperton and the University of Kent. 

This is a notable achievement and a proud moment to share with the scientific community.

Read the full article here: https://f1000research.com/articles/13-534

#LassaVirus #WHOBlueprint #ScientificResearch #Collaboration #UniversityOfKent #NigelTemperton #Virology #ResearchAchievement #vismederi 
*****************
Siamo lieti di annunciare la pubblicazione di un importante articolo sulla validazione completa del saggio di neutralizzazione dei pseudo-tipi lentivirali per il virus Lassa, uno dei virus Blue Print dellOMS. Questo significativo lavoro è stato realizzato in collaborazione con il Prof. Nigel Temperton e lUniversità del Kent.

Questo è un notevole traguardo e un momento di orgoglio da condividere con la comunità scientifica.

Leggi larticolo: https://f1000research.com/articles/13-534

#VisMederigroup #VirusLassa #OMSBlueprint #RicercaScientifica #Collaborazione #UniversitàDelKent #Virologia #TraguardoRicerca
4 weeks ago

Fabio Vedovi, Head of Quality, represented VisMederi Group at the 2024 BIO FORUM in Shanghai!

At this prestigious event, Fabio discussed potential collaborations with key industry leaders in China, focusing on groundbreaking advancements and partnerships in biotechnology and pharmaceuticals.

Stay tuned for more updates as we continue to expand our global footprint and drive innovation in the industry.

#vismederi #bioforum2024 #shanghai #biotechnology #Pharmaceuticals #innovation #GlobalCollaboration

*****

Fabio Vedovi, Responsabile della Qualità, ha rappresentato il gruppo VisMederi al BIO FORUM 2024 a Shanghai!

A questo prestigioso evento, Fabio ha discusso delle potenziali collaborazioni con i leader del settore in Cina, concentrandosi su innovazioni rivoluzionarie e partnership nel campo della biotecnologia e dei prodotti farmaceutici.

#vismederigroup #biotecnologia #farmaceutica #innovazione #collaborazioneglobale
... See MoreSee Less

Fabio Vedovi, Head of Quality, represented VisMederi Group at the 2024 BIO FORUM in Shanghai! 

At this prestigious event, Fabio discussed potential collaborations with key industry leaders in China, focusing on groundbreaking advancements and partnerships in biotechnology and pharmaceuticals.

Stay tuned for more updates as we continue to expand our global footprint and drive innovation in the industry.

#VisMederi #BIOFORUM2024 #Shanghai #Biotechnology #Pharmaceuticals #Innovation #GlobalCollaboration

*****

Fabio Vedovi, Responsabile della Qualità, ha rappresentato il gruppo VisMederi al BIO FORUM 2024 a Shanghai! 

A questo prestigioso evento, Fabio ha discusso delle potenziali collaborazioni con i leader del settore in Cina, concentrandosi su innovazioni rivoluzionarie e partnership nel campo della biotecnologia e dei prodotti farmaceutici.

#VisMederigroup #Biotecnologia #Farmaceutica #Innovazione #CollaborazioneGlobaleImage attachmentImage attachment+1Image attachment
Load more